Niraparib with Abiraterone Acetate and Prednisone for Metastatic Castration-Resistant Prostate Cancer: Phase II QUEST Study Results

Oncologist. 2023 Mar 30:oyad008. doi: 10.1093/oncolo/oyad008. Online ahead of print.ABSTRACTNiraparib (NIRA) is a highly selective inhibitor of poly (adenosine diphosphate-ribose) polymerase, PARP1 and PARP2, which play a role in DNA repair. The phase II QUEST study evaluated NIRA combinations in patients with metastatic castration-resistant prostate cancer who were positive for homologous recombination repair gene alterations and had progressed on 1 prior line of novel androgen receptor-targeted therapy. Results from the combination of NIRA with abiraterone acetate plus prednisone, which disrupts androgen axis signaling through inhibition of CYP17, showed promising efficacy and a manageable safety profile in this patient population.PMID:36994854 | DOI:10.1093/oncolo/oyad008

Source: The Oncologist - March 30, 2023 Category: Cancer & Oncology Authors: Kim N Chi Neil Fleshner Vincenzo Emanuele Chiuri Siska Van Bruwaene Jason Hafron Douglas G McNeel Peter De Porre Raymond Scott Maul Mahesh Daksh Xiaogang Zhong Gary E Mason Ronald F Tutrone Source Type: research